1.
Sylvia Snauwaert, Stijn Vanhee, Glenn Goetgeluk, Greet Verstichel, Yasmine Van Caeneghem, Imke Velghe, Jan Philippé, Zwi N. Berneman, Jean Plum, Tom Taghon, Georges Leclercq, Kris Thielemans, Tessa Kerre, Bart Vandekerckhove. RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. haematol [Internet]. 2012Oct.1 [cited 2021Nov.29];97(10):1539-47. Available from: https://haematologica.org/article/view/6440